Clinical trials: Liver Diseases, Alcoholic
Non-Alcoholic Fatty Liver Disease
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Over the past 30 years, the prevalence of childhood obesity in the United States has tripled from 5% to 15%. Major consequences of obesity include insulin resistance, type- 2 diabetes, cardiovascular disease and nonalcoholic…
- Trial name
- NCT01285362
- Testing
- Fish Oil Supplementation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Intermittent Fasting, Non-Alcoholic Fatty Liver Disease
Intermittent Fasting in Nonalcoholic Fatty Liver Disease
Although preliminary evidence suggests that intermittent fasting mimic-diet (IFD) exerts stronger effects on body weight and metabolic parameters, which may link obesity, non-alcoholic fatty liver disease (NAFLD) and major…
- Conditions
- Intermittent Fasting, Non-Alcoholic Fatty Liver Disease, Insulin Resistance, Obesity
- Trial name
- NCT04355910
- Testing
- Calorie restriction
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shaoguan University
Severe Alcoholic Hepatitis
Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis
Severity of alcoholic hepatitis is defined by Maddrey's discriminant function, value of 32 or higher indicates severe alcoholic hepatitis that carries an adverse prognosis with one month mortality of 30%-50%.
- Trial name
- NCT06155760
- Testing
- Prednisolone, Standard Medical therapy
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Sensitivity to Thyroid Hormones, Metabolic Parameters
Effects of Intermittent Fasting on Fatty Liver Disease
Eighty subjects with FLD were recruited from the endocrinology clinic at Beijing Chao-yang Hospital. All of the following inclusion criteria needed to be met: hepatic fat content (HFC) were upper 5.0% evaluated by upper abdominal…
- Conditions
- Sensitivity to Thyroid Hormones, Metabolic Parameters, in Patients With FLD
- Trial name
- NCT04795973
- Testing
- 5:2 intermittent fasting
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Chao Yang Hospital
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04669470
- Testing
- bariatric endoscopy, mainly intragastric baloons, plication of stomach too
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University of Ostrava
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic, Overweight (BMI > 25)
- Trial name
- NCT07193927
- Testing
- Lactiplantibacillus plantarum Probiotic Mixture
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- AB Biotics, SA
NAFLD, Obesity, Morbid
Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease
The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors…
- Conditions
- NAFLD, Obesity, Morbid, Comorbidities and Coexisting Conditions
- Trial name
- NCT05554224
- Testing
- To propose diagnostic tests for liver diseases before surgical decisions.
- Where
- Spain
- Volunteers
- 1,104 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Diabetes Mellitus, Diabetes Complications
Screening Patients With Diabetes Mellitus for the Presence of Skin Disorder of Scleredema
Scleredema is a scleroderma-like skin disorder appearing in 2.5-14% among patients with type 1 or 2 diabetes mellitus. This is a single centre study to screen consecutive patients with diabetes mellitus for the presence of…
- Conditions
- Diabetes Mellitus, Diabetes Complications, Scleroderma-Like Changes, Scleredema Adultorum
- Trial name
- NCT04335396
- Where
- Hungary
- Volunteers
- 150 people
- Sponsor
- University of Pecs
Non-alcoholic Fatty Liver Disease
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
This is a multi-center, double blind, parallel group placebo controlled randomised trial designed to determine the safety and efficacy of a Standardised Extract of Phyllanthus Niruri (EPN 797) HEPAR-P capsule for the treatment of…
- Trial name
- Hepar-P (NCT01680003)
- Testing
- Hepar-P
- Where
- 5 sites in Malaysia
- Volunteers
- 50 people
- Sponsor
- Nova Laboratories Sdn Bhd
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
Non Alcoholic Fatty Liver Disease, Type 2 Diabetes
Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes
The main objective of this study is to analyze the pathophysiological implications of glucagon and the incretin hormones in patients with liver disease (Non alcoholic fatty liver disease (NAFLD) or cirrhosis) with and without…
- Conditions
- Non Alcoholic Fatty Liver Disease, Type 2 Diabetes, Liver Cirrhosis
- Trial name
- NCT01492283
- Testing
- OGTT, IIGI
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Non-alcoholic Fatty Liver Disease
Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children
The aim of the present study is to find out if a dietary intervention mainly focusing on fructose reduction has a preventive effect on the development and progression of NAFLD and the metabolic syndrome in overweight children.
- Trial name
- NCT01306396
- Testing
- dietary intervention mainly focusing on fructose reduction
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Hohenheim
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Pediatric Obesity, Metabolic Syndrome
Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound…
- Conditions
- Pediatric Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver, Atherosclerosis
- Trial name
- CardMetSOb (NCT05908877)
- Testing
- History and Clinical evaluation, Biological evaluation of the metabolic syndrome and components, Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage
- Where
- Romania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neoped - Centru de Pediatrie
Liver Fibrosis Due to NASH
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants…
- Trial name
- NCT01672866
- Testing
- SIM
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 222 people
- Sponsor
- Gilead Sciences
Alcoholic Hepatitis
GCSF in Alcoholic Hepatitis
Alcoholic hepatitis is related to very high mortality rate. About 40% of the patients are died within first 6 months after the detection of the clinical syndrome.
- Trial name
- NCT03703674
- Testing
- GCSF
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non-Alcoholic Fatty Liver Disease, Obesity
Effect of L-Citrulline Supplementation on NAFLD in Adolescents With Obesity
One of the comorbidities of obesity is nonalcoholic fatty liver disease (NAFLD). L-citrulline is a non-protein amino acid that has shown positive effects on the degree of fat retention and metabolic profile in NAFLD.
- Trial name
- NCT04871360
- Testing
- L-Citrulline supplement, Carboxymethyl cellulose supplement
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Universidad de Guanajuato
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
Severe Alcoholic Hepatitis
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days.
- Trial name
- NCT01820208
- Testing
- G-CSF
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.